SLC5A2 and type 2 diabetes mellitus: Other treatment options such as sodium-glucose co-transporter 2 (SGLT2) inhibitors are recommended as the initial treatment for T2DM patients with cardiovascular diseases based on the guidelines of the European Society of Cardiology and the European Association for the study of Diabetes (Cosentino et al., 2020).